Interviews

Manmeet Ahluwalia, MD, Cleveland Clinic, discusses treatments that are showing promise for patients with lung cancer who develop brain metastases.

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.

Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials  in patients with multiple myeloma.

Manmeet Ahluwalia, MD, Cleveland Clinic, discusses the prevalence of brain metastases in triple-negative brain cancer.

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the combination of targeted therapy and checkpoint blockade for the treatment of melanoma.

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the need to develop novel therapies in mantle cell lymphoma, including a study that explored the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors.

Nadine Housri, MD, assistant clinical professor, Yale School of Medicine, discusses theMednet.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the learning curve for minimally invasive surgery in gastrointestinal cancers.

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial in non-Hodgkin lymphoma.

Dr. John Marshall presents the Avastin MCRC pivotal trials. Follow a hypothetical patient through first- and second-line treatment with Avastin.

David R. Gandara, MD, director, Thoracic Oncology Program, and professor, UC Davis Comprehensive Cancer Center, discusses the combination of CTLA-4 agents with PD-1 and PD-L1 agents for the treatment of lung cancer.

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the decreasing incidence of colon cancer diagnosis in those over the age of 50.

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses the impact of anti-PD-1 and anti-PD-L1 agents in the treatment of merkel cell carcinoma.

Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.

Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the importance of partnering with a myeloma center when managing multiple myeloma.

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses pseudoprogression in lung cancer.

Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology and director of genitourinary research at Fox Chase Cancer Center in Philadelphia, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of patients with urothelial carcinoma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses CAR T-cell therapy for myeloma and other hematologic malignancies.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients with&nbsp;<em>BRAF V600E/K</em>-mutant metastatic melanoma who received dabrafenib (Tafinlar) plus trametinib (Mekinist) in the randomized phase III COMBI-v study.

Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the mechanism of action of selinexor for the treatment of multiple myeloma.

Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses the basis for the ongoing phase III KEYNOTE-426 trial, which is exploring pembrolizumab (Keytruda)&nbsp;plus axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive advanced metastatic renal cell carcinoma.

David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses an analysis of intra-tumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).&nbsp;

Andrea B. Apolo, MD, discusses a pooled analysis of 2 cohorts of the phase 1b JAVELIN trial, which is exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.

Ann-Lii Cheng, MD, discusses a phase III trial of lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma.

Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.